GlassScriptPhysician profile
Mubeen Mandani
NPI 1609453794
$1,692.15
in general payments reported to CMS, 2019-2025
27 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $166 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.14 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $163.32 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $112.37 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.60 | 2024-2025 | Jardiance, Synjardy, Ofev |
| Genzyme Corporation | $93.57 | 2025 | |
| Corcept Therapeutics | $90.26 | 2024-2025 | Korlym |
| Abbvie INC. | $86.29 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $74.60 | 2025 | Strensiq |
| Ucb, INC. | $71.67 | 2025 | Bimzelx |
| Xeris Pharmaceuticals, INC. | $71.59 | 2025 | Keveyis, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $71.41 | 2025 | Airsupra, Saphnelo, Breztri |
| Ani Pharmaceuticals, INC. | $62.96 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $61.36 | 2025 | |
| Verity Pharmaceuticals INC. | $46.93 | 2025 | Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.02 | 2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.92 | 2025 | Arexvy, Shingrix |
| Janssen Biotech, INC. | $41.17 | 2025 | Tremfya |
| Pfizer INC. | $39.11 | 2025 | |
| Amgen INC. | $29.58 | 2025 | Otezla, Repatha |
| Invivyd INC | $28.88 | 2025 | Pemgarda |
| Edwards Lifesciences Corporation | $28.28 | 2025 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $24.11 | 2025 | Nexletol |
| Sequel Med Tech, LLC | $22.81 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $19.91 | 2025 | |
| Organon LLC | $19.51 | 2025 | Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $19.17 | 2025 | Glassia |
| Dynavax Technologies Corporation | $15.61 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mubeen Mandani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.